SLC5A2 and type 2 diabetes mellitus: Dapagliflozin was the first SGLT-2 inhibitor approved for the treatment of T2D (in Europe in 2012 and in the United States in 2014), followed by empagliflozin, canagliflozin, and ertugliflozin.